SPO16 Antibody

What is SPO16 and what is its biological function?

SPO16 is a protein involved in meiotic homologous recombination. It localizes to recombination nodules along with SHOC1 and TEX11 during meiotic prophase I. The primary function of SPO16 includes stabilization of SHOC1 and ensuring proper localization of other ZMM (Zip1, Zip2, Zip3, Zip4, Msh4, Msh5) proteins . SPO16 plays a critical role in crossover formation during meiosis, ensuring proper chromosome segregation. Research using knockout models has demonstrated that SPO16 is essential for fertility in both males and females, highlighting its importance in gamete formation and reproductive biology .

What phenotypes are observed in SPO16 knockout models?

SPO16 knockout mice exhibit complete sterility in both males and females. In male mice, spermatogenesis is arrested at meiotic prophase I, accompanied by massive apoptosis of germ cells as confirmed by cleaved caspase 3 immunostaining . Importantly, the loss of germ cells is not due to defects in spermatogonia or meiosis entry, as demonstrated by normal PLZF and MVH expression patterns . In female mice, SPO16 deletion causes smaller ovaries and premature ovarian failure, indirectly leading to obesity in adult females. Massive oocyte loss occurs between E17.5 and PD1, resulting from ectopic DNA damage signaling detected by γH2AX immunofluorescence staining .

What are the specifications of commercially available SPO16 antibodies?

Current commercial SPO16 antibodies include rabbit polyclonal antibodies suitable for Western blot (WB) and immunocytochemistry/immunofluorescence (ICC/IF) applications. For example, the A306119 anti-SPO16 antibody is generated against a recombinant fusion protein containing amino acids 47-173 of mouse C1orf146 (NP_877422.2) . This antibody demonstrates reactivity with mouse and rat samples and has been validated in Western blot analysis of rat testis extracts . The recommended dilutions are 1:500-1:2,000 for Western blot and 1:50-1:200 for ICC/IF applications .

How does SPO16 deficiency affect synapsis and chromosome pairing?

SPO16 deficiency leads to significant defects in synapsis and chromosome pairing during meiosis. In wild-type spermatocytes at pachynema, SYCP1 (a synapsed chromosome marker) assembles along the full length between homologs except for unpaired regions in the X-Y chromosome pair, while HORMAD1 (an unsynapsed chromosome marker) is removed from chromosome axes and retained only on unpaired regions of the sex body .

In SPO16-deficient spermatocytes, complete synapsis is never observed. Instead, these cells exhibit either:

• A zygotene-like stage characterized by partial pairing and widely distributed unsynapsed zipper-like chromosome forks

• A pachytene-like stage where most chromosomes appear paired except for one "multichromosome structure"

Similarly, SPO16-deleted female primordial germ cells (PGCs) arrest at a zygotene-like stage due to failure in synaptonemal complex (SC) assembly along chromosome pairs . These defects in synapsis have been confirmed by staining with additional SC components such as SIX6OS1.

What is the relationship between SPO16 and other meiotic recombination proteins?

SPO16 functions within a network of proteins critical for meiotic recombination. It binds to SHOC1 and is required for the stabilization of SHOC1 and proper localization of other ZMM proteins . The functional relationship between SPO16 and other recombination proteins resembles that seen in the broader meiotic recombination machinery.

While not directly addressed in the search results for SPO16, the meiotic context involves SPO11, which initiates meiotic recombination by creating DSBs. SPO11 has two splice isoforms, SPO11β and SPO11α, which are expressed at different times during meiosis and have distinct roles . This regulatory complexity likely extends to the SPO16 interaction network as well, though the specific interactions require further investigation.

How can researchers distinguish between the effects of SPO16 deletion versus other ZMM protein deficiencies?

To distinguish between SPO16 deletion effects and deficiencies of other ZMM proteins, researchers should implement a comparative analysis approach. This should include:

• Phenotypic comparison: Analyze meiotic progression, fertility outcomes, and cellular abnormalities across different knockout models

• Protein localization studies: Examine the interdependence of protein localization (e.g., determining if SHOC1 localization depends on SPO16 and vice versa)

• Genetic interaction studies: Create double mutants to analyze synthetic effects or epistatic relationships

• Biochemical interaction analysis: Perform co-immunoprecipitation and other protein-protein interaction assays

The SPO16 knockout phenotype can be compared with other well-studied knockouts like DMC1 and SPO11, which are commercially available from the Jackson Laboratory and have been used as controls in SPO16 studies .

What are the optimal conditions for using SPO16 antibodies in Western blot analysis?

For optimal Western blot analysis using SPO16 antibodies, researchers should follow these guidelines:

• Sample preparation: Extracts from testicular tissue (particularly effective with rat testis) have been validated for SPO16 detection

• Antibody dilution: Use a dilution range of 1:500-1:2,000, with 1:1,000 being recommended based on published validation data

• Detection system: Compatible with standard secondary antibodies including HRP-conjugated anti-rabbit IgG

• Expected molecular weight: SPO16 protein appears at approximately 20 kDa

• Storage conditions: Upon delivery, aliquot the antibody and store at -20°C to avoid freeze/thaw cycles, which may affect antibody performance

For researchers using A306119 anti-SPO16 antibody, the formulation includes phosphate-buffered saline (pH 7.3) with 50% glycerol and 0.01% thiomersal , which should be considered when designing experiments.

How should SPO16 antibodies be used for immunofluorescence staining of meiotic spreads?

For immunofluorescence staining of meiotic spreads to detect SPO16:

• Dilution: Use the SPO16 antibody at a dilution of 1:50-1:200 based on validated protocols

• Co-staining markers:

  • Include synapsed chromosome markers like SYCP1 and unsynapsed chromosome markers like HORMAD1 to identify meiotic stages accurately

  • Consider additional markers such as SIX6OS1 (another central element of SC) for confirmation of synapsis defects

• Controls:

  • Positive control: Include wild-type samples processed identically to experimental samples

  • Negative control: Include SPO16 knockout samples or isotype controls (Rabbit IgG) to confirm antibody specificity

• Detection system: Use appropriate fluorophore-conjugated secondary antibodies such as goat anti-rabbit IgG H&L antibody (FITC)

This approach has been successfully used to characterize synapsis defects in SPO16-deficient spermatocytes and oocytes .

What controls are essential when studying SPO16 function and localization?

When studying SPO16 function and localization, the following controls are essential:

• Genetic controls:

  • Wild-type samples as positive controls

  • SPO16 knockout samples as negative controls

  • Known meiotic mutants (e.g., DMC1-/- and SPO11-/- mice) as comparative controls

• Antibody controls:

  • Isotype controls (Rabbit IgG A82272 or A17360) to verify specific binding

  • Secondary antibody-only controls to check for background staining

  • Dilution series to optimize signal-to-noise ratio

• Technical controls:

  • Multiple detection methods (Western blot, immunofluorescence) to confirm findings

  • Multiple tissue types or developmental stages when studying temporal expression

  • Counterstaining with DNA markers (e.g., DAPI) and other protein markers to accurately assess co-localization

• Validation strategies:

  • Confirm genotypes by PCR and sequencing of genomic DNA from heterozygous and homozygous knockout mice

  • Use multiple antibodies targeting different epitopes when available

  • Include positive markers like PLZF (for undifferentiated spermatogonia) and MVH (for germ cells) to rule out non-specific effects

What are common issues when using SPO16 antibodies and how can they be resolved?

Common issues when using SPO16 antibodies include:

• High background signal:

  • Solution: Increase blocking time and concentration, optimize antibody dilution (try 1:1,000-1:2,000 for Western blot, 1:100-1:200 for ICC/IF)

  • Increase washing steps duration and number

  • Use freshly prepared buffers

• Weak or absent signal:

  • Solution: Reduce antibody dilution (try 1:500 for Western blot, 1:50 for ICC/IF)

  • Optimize antigen retrieval methods for fixed tissues

  • Ensure proper sample preparation (fresh tissue extracts work best)

  • Check storage conditions (-20°C with minimal freeze/thaw cycles)

• Non-specific bands in Western blot:

  • Solution: Increase antibody specificity by using more stringent washing conditions

  • Confirm results with knockout controls

  • Try alternative blocking reagents

• Inconsistent results across experiments:

  • Solution: Standardize protocols rigorously

  • Prepare larger batches of antibody dilutions to use across multiple experiments

  • Document lot-specific concentration and test each new lot

How can researchers validate SPO16 antibody specificity in their experimental system?

To validate SPO16 antibody specificity in experimental systems:

• Genetic validation:

  • Compare staining patterns between wild-type and SPO16 knockout tissues

  • If knockout models aren't available, use siRNA or CRISPR-Cas9 to reduce SPO16 expression and confirm reduced antibody signal

• Biochemical validation:

  • Perform peptide competition assays using the immunogen sequence (amino acids 47-173 of mouse C1orf146)

  • Use Western blot to confirm the detection of a single band at the expected molecular weight (20 kDa)

• Cross-validation:

  • Compare results from multiple antibodies targeting different epitopes of SPO16

  • Validate results using complementary techniques (e.g., mass spectrometry)

• Spatial and temporal expression analysis:

  • Confirm that expression patterns match known biology (e.g., high expression in testicular tissue)

  • Verify that developmental timing of expression matches expected patterns (e.g., during meiotic prophase I)

What emerging techniques might enhance SPO16 antibody applications in research?

Emerging techniques that may enhance SPO16 antibody applications include:

• Super-resolution microscopy:

  • Techniques like STORM, PALM, or SIM could resolve the precise localization of SPO16 at recombination nodules beyond the diffraction limit

  • Would clarify spatial relationships between SPO16 and other ZMM proteins during meiosis

• Proximity labeling approaches:

  • BioID or APEX2 fusions to SPO16 could identify novel interaction partners in living cells

  • Would complement existing knowledge about SPO16's relationship with SHOC1

• CUT&RUN or CUT&Tag:

  • These techniques offer higher resolution and lower background than ChIP for profiling protein-DNA interactions

  • Could clarify if SPO16 has direct interactions with DNA during recombination

• Single-cell approaches:

  • Analyzing SPO16 expression and localization at the single-cell level would reveal cell-to-cell variability in meiotic processes

  • Could identify rare intermediate states in recombination

• CRISPR-based protein tagging:

  • Endogenous tagging of SPO16 would allow live-cell imaging without overexpression artifacts

  • Would provide temporal information about SPO16 dynamics during meiosis

How might SPO16 research contribute to understanding fertility issues?

SPO16 research has significant implications for understanding fertility issues:

• Diagnostic potential:

  • SPO16 mutations or abnormal expression could be screened in cases of unexplained infertility

  • The protein's essential role in both male and female fertility makes it a candidate gene for comprehensive fertility assessments

• Mechanistic insights:

  • Understanding how SPO16 deficiency causes premature ovarian failure could illuminate pathways involved in age-related female fertility decline

  • The massive oocyte loss observed between E17.5 and PD1 in SPO16-deficient mice provides a model for studying early oocyte attrition

• Comparative studies:

  • Analyzing SPO16 function across species could reveal evolutionarily conserved mechanisms of meiotic recombination

  • May help explain species-specific differences in fertility and reproductive strategies

• Therapeutic development:

  • Long-term research could potentially identify intervention points in the meiotic recombination pathway

  • Understanding SPO16's role in preventing ectopic DNA damage signaling might inform approaches to protect oocyte reserves

The sterility phenotype observed in both male and female SPO16 knockout mice, coupled with the specific meiotic defects, positions SPO16 as an important factor in the study of human fertility disorders .

How should researchers interpret SPO16 staining patterns in relation to meiotic progression?

When interpreting SPO16 staining patterns in relation to meiotic progression, researchers should consider:

• Temporal dynamics:

  • SPO16 localizes to recombination nodules during meiotic prophase I

  • Compare patterns to established meiotic stage markers: SYCP1 for synapsed chromosomes and HORMAD1 for unsynapsed regions

• Spatial distribution:

  • In wild-type cells, expect punctate staining along chromosome axes

  • Patterns should correlate with markers of homologous recombination sites

  • Co-localization with SHOC1 and other ZMM proteins should be evident

• Stage-specific patterns:

  • At pachynema in wild-type cells, SYCP1 assembles to full length between homologs except for unpaired regions in the X-Y pair, with HORMAD1 only retained on unpaired regions

  • In SPO16-deficient cells, incomplete synapsis results in either zygotene-like patterns (partial pairing with zipper-like chromosome forks) or pachytene-like patterns (most chromosomes paired except for a "multichromosome structure")

• Quantitative assessment:

  • Count SPO16 foci per nucleus across different meiotic stages

  • Measure co-localization coefficients with other proteins

  • Compare these metrics between experimental conditions and controls

What statistical approaches are appropriate for analyzing SPO16 immunostaining data?

For robust analysis of SPO16 immunostaining data, researchers should consider these statistical approaches:

• For foci counting and distribution analysis:

  • Calculate mean, median, and range of SPO16 foci per nucleus

  • Use non-parametric tests (Mann-Whitney U test or Kruskal-Wallis) for comparing foci numbers between experimental groups

  • Analyze the distribution of foci using cumulative frequency distributions

• For co-localization analysis:

  • Calculate Pearson's or Mander's correlation coefficients for spatial overlap with other proteins

  • Use randomization tests to determine if observed co-localization exceeds random chance

  • Consider distance-based metrics between SPO16 foci and other structures

• For experimental comparisons:

  • Use appropriate sample sizes (typically ≥100 nuclei per condition from ≥3 biological replicates)

  • Apply multiple testing corrections (e.g., Bonferroni or FDR) when performing numerous comparisons

  • Consider mixed-effects models to account for inter-animal and inter-experimental variability

• For phenotypic analysis:

  • Quantify the proportion of cells at different meiotic stages

  • Compare cell progression between wild-type and experimental conditions

  • Correlate SPO16 staining patterns with cellular outcomes (e.g., apoptosis markers like cleaved caspase 3)